Mircera100 µg

Mircera is a long-acting erythropoiesis-stimulating agent (ESA), also known as pegylated epoetin beta or methoxy polyethylene glycol-epoetin beta (C.E.R.A.), used for the following indication:

FDA-Approved / Established Use

• Anemia associated with chronic kidney disease (CKD): Mircera is indicated for the treatment of anemia associated with CKD in adult patients, including those on dialysis and those not on dialysis.

Not Indicated For

• Mircera is not indicated for use in patients with cancer receiving chemotherapy, as a substitute for red blood cell transfusion in patients who require immediate correction of anemia, or for reduction of allogeneic blood transfusion in surgery patients — these are not established or approved uses for this specific agent.

Mircera is intended to reduce the need for red blood cell transfusions in appropriately selected patients, not to normalize hemoglobin levels.

Each pre-filled syringe/vial of Epoetin Beta [Methoxy Polyethyelene Glycol] contains methoxy polyethylene glycol-epoetin beta (a pegylated derivative of recombinant human erythropoietin produced by conjugation of epoetin beta with a linear methoxy polyethylene glycol polymer) as the active ingredient, along with pharmaceutical excipients such as sodium sulfate, sodium and potassium phosphate, mannitol, methionine, poloxamer 188, and water for injection.

Epoetin Beta [Methoxy Polyethyelene Glycol] is available in single-use pre-filled syringes/vials in a range of strengths (e.g., 30, 50, 75, 100, 120, 150, 200, 250, 360 micrograms per 0.3 mL) as a sterile, clear, colorless solution for injection.

Mircera is a long-acting erythropoiesis-stimulating agent (ESA) that stimulates erythropoiesis (red blood cell production) by the same mechanism as endogenous erythropoietin. It differs from other ESAs (such as epoetin alfa and darbepoetin alfa) by its unique interaction with the erythropoietin receptor, which results in a slower association/faster dissociation profile and a substantially longer serum half-life, allowing for extended dosing intervals (once every two weeks or once monthly).

Mircera is administered by subcutaneous or intravenous injection and is used specifically to manage anemia related to chronic kidney disease.

Mircera belongs to the therapeutic class of erythropoiesis-stimulating agents (ESAs), a subclass of antianemic preparations used in the management of anemia of chronic kidney disease.

Mechanism of Action

Epoetin Beta [Methoxy Polyethyelene Glycol] acts on the erythropoietin receptor on erythroid progenitor cells in the bone marrow in the same way as endogenous erythropoietin, stimulating their division and differentiation into mature red blood cells, thereby increasing hemoglobin and red blood cell production.

Pharmacokinetics

The methoxy polyethylene glycol moiety confers a markedly extended terminal half-life (approximately 130 hours after intravenous administration and 140 hours after subcutaneous administration in dialysis patients) compared with other ESAs, permitting once-every-2-weeks or once-monthly dosing. Bioavailability after subcutaneous injection is approximately 54%. Steady-state hemoglobin levels are typically reached within about 12 weeks of dose titration.

Mircera is administered by subcutaneous (SC) or intravenous (IV) injection. It is supplied as a ready-to-use sterile solution in a pre-filled syringe and does not require reconstitution or dilution.

• Inspect the solution visually; do not use if discolored or if particulate matter is present.
• Do not shake the syringe vigorously, as this may denature the protein.
• Allow the syringe to reach room temperature before injection.
• Rotate subcutaneous injection sites (abdomen, thigh, or upper arm).
• Each syringe is for single use only; discard any unused portion.

No formal drug-drug interaction studies have been conducted with Mircera. Erythropoiesis-stimulating agents as a class do not have well-established, clinically significant pharmacokinetic drug interactions. The following points are clinically relevant:

• Iron supplements: Adequate iron stores are required for an effective erythropoietic response; iron supplementation is often needed concurrently and does not reduce efficacy, but iron status should be monitored.
• Other erythropoiesis-stimulating agents: Mircera should not be used concurrently with other ESAs due to overlapping mechanism and additive risk of excessive hemoglobin response.

The most commonly reported adverse reactions with Mircera include:

• Hypertension
• Diarrhea
• Nasopharyngitis / upper respiratory tract infection
• Headache
• Arthralgia
• Hypotension
• Cough
• Vascular access thrombosis (in dialysis patients)
• Nausea and peripheral edema

Serious but less common reactions include serious allergic/hypersensitivity reactions, and the boxed-warning risks (cardiovascular events, thrombosis, tumor progression) described under Precautions and Warnings.

Data on the use of Mircera in pregnant women are limited. Mircera should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, and only under close physician supervision.

It is not known whether Mircera is excreted in human milk; because many drugs are excreted in human milk, caution should be exercised, and a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother, in consultation with a physician.

Boxed Warning — Class Risks of ESAs

Mircera, like all erythropoiesis-stimulating agents, increases the risk of death, myocardial infarction, stroke, venous thromboembolism, and thrombosis of vascular access when administered to target a hemoglobin level greater than the recommended range. In patients with cancer, ESAs have been shown to increase the risk of tumor progression or recurrence in some settings.

• Use the lowest dose of Mircera sufficient to reduce the need for red blood cell transfusion.
• Do not exceed the hemoglobin target recommended in the approved labeling; avoid rapid increases in hemoglobin.
• Monitor blood pressure regularly; treat hypertension before and during therapy, as uncontrolled hypertension is a contraindication (see Contraindications).
• Monitor hemoglobin and iron status (ferritin, transferrin saturation) periodically throughout treatment.
• Evaluate for loss of response or failure to maintain hemoglobin response, which may indicate antibody-mediated pure red cell aplasia (PRCA); if suspected, discontinue Mircera and do not switch to another ESA (see Contraindications).
• Serious allergic reactions, including anaphylaxis, have been reported; discontinue immediately if a serious hypersensitivity reaction occurs.
• Increased mortality and/or increased risk of tumor progression/recurrence has been observed in some studies when ESAs were administered to certain cancer patients; Mircera is not approved for this use.

Overdosage of Mircera can lead to polycythemia (excessive red blood cell production), which may manifest as symptoms related to hyperviscosity of the blood such as severe hypertension, headache, or thrombotic events. There is no specific antidote for Mircera overdose.

If overdose is suspected, seek immediate medical attention or contact emergency services / a poison control center. Management is supportive; phlebotomy may be performed as clinically indicated under medical supervision, and Mircera therapy should be temporarily withheld with close monitoring of hemoglobin and blood pressure.

Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze; discard if the product has been frozen. Protect from light by keeping the syringe in its original carton until time of use. If needed, may be kept at room temperature (up to 30°C) for a single period of up to one month, then discarded if not used. Keep out of reach of children.

Renal Impairment

Mircera is specifically indicated for anemia of chronic kidney disease; dosing is titrated based on hemoglobin response regardless of dialysis status, as described in Dosage and Administration.

Hepatic Impairment

No formal studies have established dose adjustment requirements in hepatic impairment; use with caution and monitor closely.

Elderly

No overall differences in safety or effectiveness have been observed between elderly and younger patients, but greater sensitivity in some older individuals cannot be ruled out; use standard monitoring.

Pediatric Patients

Safety and efficacy of Mircera have not been established in pediatric patients (see Pediatric Uses).

Mircera is intended for long-term, chronic management of anemia associated with chronic kidney disease, with treatment continued as long as clinically indicated and hemoglobin remains within the target range. Dose and dosing interval are periodically reassessed (approximately every 4 weeks, or as clinically indicated) based on hemoglobin trends, iron status, and clinical response. There is no fixed maximum duration of therapy; the physician determines continued need based on ongoing anemia and risk-benefit assessment.

Erythropoiesis-stimulating agent (ESA); antianemic preparation; recombinant human erythropoietin derivative (pegylated).

Epoetin Beta [Methoxy Polyethyelene Glycol] binds to and activates the erythropoietin receptor on erythroid progenitor cells in the bone marrow, triggering intracellular signaling pathways (via JAK2/STAT5) that promote proliferation, differentiation, and survival of these progenitors into mature erythrocytes. Its pegylation with methoxy polyethylene glycol reduces receptor-binding affinity but slows clearance, giving a distinctive pharmacokinetic/pharmacodynamic profile characterized by a much longer circulating half-life than non-pegylated epoetins, enabling extended dosing intervals while achieving comparable erythropoietic effect.

C

The safety and efficacy of Mircera have not been established in pediatric patients. Use in this population is not recommended outside of specialist supervision until further data become available.